Compare COCO & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COCO | TLX |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.3B |
| IPO Year | 2021 | N/A |
| Metric | COCO | TLX |
|---|---|---|
| Price | $53.69 | $7.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $55.13 | $21.00 |
| AVG Volume (30 Days) | ★ 623.0K | 193.1K |
| Earning Date | 10-29-2025 | 01-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.16 | N/A |
| EPS | ★ 1.15 | 0.04 |
| Revenue | $609,286,000.00 | ★ $664,225,558.00 |
| Revenue This Year | $18.22 | N/A |
| Revenue Next Year | $13.69 | N/A |
| P/E Ratio | ★ $46.37 | $181.75 |
| Revenue Growth | 23.12 | ★ 55.35 |
| 52 Week Low | $25.79 | $7.72 |
| 52 Week High | $55.29 | $30.36 |
| Indicator | COCO | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 58.27 | 30.67 |
| Support Level | $52.87 | $7.72 |
| Resistance Level | $54.89 | $8.22 |
| Average True Range (ATR) | 1.33 | 0.25 |
| MACD | -0.36 | -0.06 |
| Stochastic Oscillator | 61.66 | 1.31 |
The Vita Coco Co Inc is a plant-based functional hydration platform. Its products include Vita Coco Coconut Water, Private Label including coconut water and oil, and Other including Runa, Ever & Ever, and PWR LIFT product offerings, Vita Coco product extensions beyond coconut water, such as Vita Coco Sparkling, coconut milk products, and others. The company has two segments: The Americas segment which comprises of operations in the U.S. and Canada; and The International segment that comprises of operations in Europe, the Middle East, Africa and the Asia Pacific regions. The Americas segment derives maximum revenue. Geographical presence of the company is in United States, United Kingdom and All other countries.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.